Dow Down0.22% Nasdaq Up0.14%

Transcept Pharmaceuticals, Inc. (TSPT)

2.22 Up 0.01(0.45%) Aug 22, 4:00PM EDT
ProfileGet Profile for:
Transcept Pharmaceuticals, Inc.
1003 West Cutting Boulevard
Suite 110
Point Richmond, CA 94804
United States - Map
Phone: 510-215-3500

Index Membership:N/A
Full Time Employees:8

Business Summary 

Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of proprietary products that address therapeutic needs in the field of neuroscience. The company principal product include Intermezzo sublingual tablet C-IV, a sublingual formulation of zolpidem for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Its lead product candidate is TO-2070, a rapidly absorbed treatment for acute migraine. The company has a collaboration agreement with Purdue Pharmaceutical Products, L.P. for the commercialization of Intermezzo in the United States, as well as granted the right to negotiate for the commercialization of Intermezzo in Mexico and Canada. Transcept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Point Richmond, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Transcept Pharmaceuticals, Inc.

Corporate Governance 
Transcept Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Glenn A. Oclassen Sr., 71
Chairman, Chief Exec. Officer and Pres
Ms. Leone D. Patterson , 51
Chief Financial Officer, Principal Accounting Officer and VP
Dr. Nikhilesh N. Singh Ph.D., 56
Chief Scientific Officer and Sr. VP
Mr. John A. Kollins MBA, 51
Chief Bus. Officer and Sr. VP
Mr. Greg Mann ,
Sr. Director of Corp. Communications
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders